Serina Therapeutics' Chief Scientific Officer Executes Stock Sale Amid Equity Concerns
On January 22, 2026, Serina Therapeutics’ Chief Scientific Officer, Randall Moreadith, disposed of 2,500 shares of common stock at $2.95 per share, totaling $7,375. This sale came despite the stock trading lower at $2.72 and a 46.47% decline over six months. Concurrently, Moreadith exercised options for 2,500 shares at a $0.06 exercise price. Serin…